Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · IEX Real-Time Price · USD
2.700
+0.050 (1.89%)
At close: Jul 19, 2024, 12:00 AM
2.690
-0.010 (-0.37%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 20 employees as of December 31, 2023. The number of employees increased by 3 or 17.65% compared to the previous year.
Employees
20
Change (1Y)
3
Growth (1Y)
17.65%
Revenue / Employee
n/a
Profits / Employee
-$1,992,450
Market Cap
103.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
So-Young International | 1,357 |
FibroGen | 486 |
InterCure | 270 |
Adicet Bio | 143 |
IO Biotech | 68 |
VistaGen Therapeutics | 40 |
Cardiff Oncology | 32 |
Zentek | 24 |
ELDN News
- 19 days ago - Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism - GlobeNewsWire
- 6 weeks ago - Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress - GlobeNewsWire
- 2 months ago - Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection - GlobeNewsWire
- 4 months ago - Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results - GlobeNewsWire
- 4 months ago - Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection - GlobeNewsWire
- 4 months ago - Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human - GlobeNewsWire